- Home
- KALV vs BCYC Comparison
KALV vs BCYC Comparison
Compare KALV & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- BCYC
- Stock Information
- Founded
- KALV N/A
- BCYC 2009
- Country
- KALV United States
- BCYC United Kingdom
- Employees
- KALV N/A
- BCYC N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- KALV Health Care
- BCYC Health Care
- Exchange
- KALV Nasdaq
- BCYC Nasdaq
- Market Cap
- KALV 637.9M
- BCYC 566.5M
- IPO Year
- KALV N/A
- BCYC 2019
- Fundamental
- Price
- KALV $12.34
- BCYC $7.56
- Analyst Decision
- KALV Strong Buy
- BCYC Buy
- Analyst Count
- KALV 9
- BCYC 10
- Target Price
- KALV $26.29
- BCYC $22.44
- AVG Volume (30 Days)
- KALV 1.0M
- BCYC 260.8K
- Earning Date
- KALV 09-04-2025
- BCYC 08-08-2025
- Dividend Yield
- KALV N/A
- BCYC N/A
- EPS Growth
- KALV N/A
- BCYC N/A
- EPS
- KALV N/A
- BCYC N/A
- Revenue
- KALV N/A
- BCYC $19,281,000.00
- Revenue This Year
- KALV N/A
- BCYC $7.35
- Revenue Next Year
- KALV $192.67
- BCYC N/A
- P/E Ratio
- KALV N/A
- BCYC N/A
- Revenue Growth
- KALV N/A
- BCYC N/A
- 52 Week Low
- KALV $7.30
- BCYC $6.10
- 52 Week High
- KALV $16.32
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- KALV 36.00
- BCYC 39.89
- Support Level
- KALV $12.19
- BCYC $7.36
- Resistance Level
- KALV $14.35
- BCYC $7.98
- Average True Range (ATR)
- KALV 0.61
- BCYC 0.40
- MACD
- KALV -0.30
- BCYC -0.12
- Stochastic Oscillator
- KALV 5.26
- BCYC 7.68
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.